Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation.
OBJECTIVE
De novo autoimmune hepatitis (AIH) recently was recognized as an important cause of late graft dysfunction after pediatric liver transplantation (LT). However, the significance of isolated elevation of autoantibodies in children after LT without history of prior autoimmune liver disease scarcely has been studied. The aim of the present study was to determine the prevalence and risk factors for autoantibodies production in pediatric LT recipients and to assess the impact of isolated elevation of autoantibodies over time on graft function.


METHODS
Sixty-eight children without history of autoimmune disease were recruited over the course of 1 year into this cross-sectional study. A single blood specimen was drawn at study entry to determine titers of autoantibodies. Clinical and laboratory assessment and medical history were obtained at study entry as well. Patients were then divided into positive and negative autoantibodies groups, and prospectively followed for 18 months for evidence of abnormal liver function tests.


RESULTS
One or more autoantibodies were detected in 18 (26%) patients. Anti-smooth muscle was the most common (n = 13) antibody. Time since transplant (>4 years) was the only risk factor identified for the presence of autoantibodies (univariate risk ratio, 3.3; 95% confidence interval, 1.2-9). During the follow-up period, 5 patients with positive autoantibody screen developed de novo AIH (n = 3) or chronic rejection (n = 2), compared with 0 in the negative autoantibody group. Children with positive autoantibody screen were at higher risk for development of de novo AIH or chronic rejection (univariate risk ratio 13.9; 95% confidence interval, 1.7-111; P = 0.004).


CONCLUSIONS
Positive autoantibodies are common in children after LT and their presence may denote a higher risk for the development of de novo AIH or chronic rejection over time.
Paediatric Academic Multi-organ Transplantation (PAMOT) Program, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. yarona@clalit.org.il
Yaron
Y
Avitzur
Bo Y
BY
Ngan
Michelle
M
Lao
Annie
A
Fecteau
Vicky Lee
VL
Ng
D000293:Adolescent; D001323:Autoantibodies / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006084:Graft Rejection / Q000453:epidemiology* / Q000276:immunology; D019693:Hepatitis, Autoimmune / Q000453:epidemiology* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D009130:Muscle, Smooth / Q000276:immunology; D011183:Postoperative Complications / Q000453:epidemiology* / Q000276:immunology; D015995:Prevalence; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors
D001323:Autoantibodies; D007166:Immunosuppressive Agents